Market Intelligence, Clinical Progress, and High-Purity Reagents for Hedgehog Pathway Oncology Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for CDON drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | CDON ECD-Fc Fusion Protein. HEK293 expressed, >95% purity, Endotoxin <1EU/µg. Sequence Verified. Includes 3 Ig-like C2-type domains (UniProt Q4KMG0). | View CDON Products |
| Gene Delivery | CDON Promise-ORF / Lentivirus. Full-length human CDON ORF (NM_016952) for stable cell line construction. Puromycin selectable. | View CDON Products |
| Benchmark Ab | Anti-CDON (Sequence-Defined Positive Control). Recombinant monoclonal for assay calibration and neutralization assays. | View CDON Products |
| Validator | CDON siRNA Set (3 unique sequences). >85% knockdown efficiency validated. For specificity controls. | View CDON Products |
| BOC (Counter-Screen) | BOC ECD-Fc Protein. Brother of CDO – close homolog (68% ECD identity). Essential for off-target liability screening. | View BOC Products |
| SHH (Pathway) | Sonic Hedgehog Recombinant Protein. Ligand for functional Hedgehog pathway activation assays. | View SHH Products |
| PTCH1 (Coreceptor) | PTCH1 ECD Protein. Hedgehog receptor complex partner; essential for resistance mechanism studies and trimeric complex assays. | View PTCH1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Complex Mammalian Glycosylation | HEK293 expressed (native glycosylation) preserves structural integrity of the large extracellular domain with 3 Ig-like regions. |
| Homolog Cross-Reactivity (BOC vs CDON) | Homolog panel (CDON, BOC, NEO1) strictly verified by mass spec and Sequence Verified; distinct domain boundaries. |
| Internalization Efficiency (ADC Development) | Full-length Lentivirus particles preserve native conformation and glycosylation for accurate antibody uptake quantification. |
| Cross-Species Translation (Toxicology) | Human/Mouse/Cyno CDON ECD ortholog proteins available, sequence-aligned for epitope conservation analysis. |
| Lack of Validated Cell Models | Premade Lentivirus for robust stable cell line construction; ensures native CDON membrane topology. |
| False Positives in Screening | High purity (>95%) antigens and specific siRNA set included for background reduction and specificity checks. |
Live CDON R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for Hedgehog (Hh) pathway therapeutics is intensifying, with major players shifting focus from traditional downstream SMO inhibitors—which are increasingly plagued by drug resistance mutations—to upstream targets like CDON. As an essential co-receptor for Hedgehog signaling that is overexpressed in various solid tumors (including prostate, lung, gastrointestinal cancers, neuroblastoma, and rhabdomyosarcoma), CDON presents a highly attractive target. First-generation SMO inhibitors (Vismodegib, Sonidegib) face clinical resistance through PTCH1/SMO mutations, driving the next wave of R&D toward CDON-directed Antibody-Drug Conjugates (ADCs), bispecifics, and CAR-T modalities. CDON’s restricted expression in normal adult tissues and tumor-specific upregulation make it a compelling target for oncology. The near-term outlook (3–5 years) predicts expansion of ADC programs into pediatric neuroblastoma (orphan drug pathway) and combination strategies with immune checkpoint inhibitors.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| ADC | Emerging Biotech, Academic Labs | Neuroblastoma, SCLC, Prostate, GI | Internalization Assay (Need high-purity ECD-Fc & Lentivirus for binding kinetics and uptake quantification) |
| Monoclonal Antibody | Discovery-stage biotechs, Academic groups | Rhabdomyosarcoma, Medulloblastoma | Receptor-Ligand Blocking Assay (Need structural fidelity HEK293 Antigens for epitope binning) |
| Bispecific (CDON x CD3, CDON x BOC) | Immuno-oncology Innovators | Refractory Cancers, SMO-resistant tumors | Selectivity Assay (Need Homolog counter-screens against BOC/PTCH1; ortholog panel for cross-reactivity) |
| CAR-T Cell Therapy | Academic Medical Centers | Relapsed/Refractory Solid Tumors | Stable Cell Line Construction (Full-length CDON Lentivirus for target cell engineering) |
| Small Molecule Combo | Pharma discovery groups | Basal Cell Carcinoma, RMS | Pathway Reporter & Selectivity Assay (Need full-length Lentivirus cell lines and SHH ligand) |